Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday. Shares of both companies tumbled Tuesday morning in the first day of trading after Cubist said a federal court invalidated four patents protecting Cubicin.